Pediatrix Medical Group, Inc. (NYSE:MD) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Pediatrix Medical Group, Inc. (NYSE:MD) have been given a consensus recommendation of “Hold” by the five analysts that are currently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $10.90.

MD has been the topic of several recent research reports. Jefferies Financial Group upgraded shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating and increased their target price for the stock from $8.00 to $14.00 in a report on Thursday, September 26th. Truist Financial increased their target price on shares of Pediatrix Medical Group from $10.00 to $13.00 and gave the stock a “hold” rating in a report on Monday, October 7th. StockNews.com upgraded shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a report on Wednesday, August 7th. Finally, UBS Group increased their target price on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a report on Friday, August 9th.

Insider Activity

In other news, Director Laura A. Linynsky sold 7,000 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total value of $78,120.00. Following the sale, the director now directly owns 30,805 shares in the company, valued at approximately $343,783.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO C Marc Richards sold 32,562 shares of the stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $10.08, for a total value of $328,224.96. Following the completion of the transaction, the chief financial officer now directly owns 192,785 shares of the company’s stock, valued at $1,943,272.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Laura A. Linynsky sold 7,000 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total transaction of $78,120.00. Following the completion of the transaction, the director now directly owns 30,805 shares of the company’s stock, valued at $343,783.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 68,100 shares of company stock worth $701,889. Corporate insiders own 2.00% of the company’s stock.

Hedge Funds Weigh In On Pediatrix Medical Group

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Pediatrix Medical Group by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock valued at $105,892,000 after purchasing an additional 164,333 shares during the last quarter. Rubric Capital Management LP raised its position in Pediatrix Medical Group by 797.0% during the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after buying an additional 7,241,400 shares during the last quarter. Boston Partners raised its position in Pediatrix Medical Group by 34.0% during the 1st quarter. Boston Partners now owns 1,786,434 shares of the company’s stock worth $17,702,000 after buying an additional 453,254 shares during the last quarter. Dana Investment Advisors Inc. raised its position in Pediatrix Medical Group by 80.3% during the 2nd quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock worth $7,725,000 after buying an additional 455,785 shares during the last quarter. Finally, Brandes Investment Partners LP raised its position in Pediatrix Medical Group by 12.8% during the 2nd quarter. Brandes Investment Partners LP now owns 735,068 shares of the company’s stock worth $5,438,000 after buying an additional 83,588 shares during the last quarter. 97.71% of the stock is owned by hedge funds and other institutional investors.

Pediatrix Medical Group Trading Up 3.1 %

NYSE MD opened at $12.67 on Thursday. The company’s 50-day moving average price is $11.04 and its 200-day moving average price is $9.11. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.87. The stock has a market cap of $1.07 billion, a PE ratio of -14.91, a PEG ratio of 1.84 and a beta of 1.56. Pediatrix Medical Group has a 12 month low of $6.62 and a 12 month high of $13.01.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.03. The firm had revenue of $504.30 million for the quarter, compared to analysts’ expectations of $505.49 million. Pediatrix Medical Group had a negative net margin of 12.58% and a positive return on equity of 10.59%. The business’s revenue for the quarter was up .7% on a year-over-year basis. During the same period in the prior year, the business posted $0.37 earnings per share. Equities research analysts forecast that Pediatrix Medical Group will post 1.19 earnings per share for the current year.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.